Maze Therapeutics (MAZE) Change in Receivables (2026)

Maze Therapeutics recorded quarterly Change in Receivables of $20.0 million in Q1 2026.

Maze Therapeutics' Change in Receivables history runs 1 years deep, the most recent figure standing at $20.0 million for Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Receivables (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 208,524.00
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -39.80 Mn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -1.20 Mn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 110.42 Mn
10 Maze Therapeutics 1.37 Bn 1.37 Bn 18.21 Mn 20.00 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 20.00 Mn
Mar 31, 2026 20.00 Mn